Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The study purpose is to assess the impact of an educational program on patient adherence in patients taking Apixaban for SPAF at 24 weeks
Full description
SPAF=Stroke Prevention in Atrial Fibrillation
ISTH=International Society on Thrombosis and Hemostasis
Primary Purpose: Other: To measure adherence to the study medication using an electronic monitoring device over the first 24 weeks on study medication
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients with diagnosed non-valvular Atrial Fibrillation (AF) or atrial flutter (documented by 12-lead electrocardiogram (ECG) or Holter recording) and eligible for oral anticoagulant (OAC) therapy
Presence of at least one of the following risk factors for stroke:
Prior stroke or transient ischaemic attack (TIA)
Must be able to self-administer treatment
Either Vitamin K antagonists (VKA) treated or VKA naive. Patients treated with VKA should have received the VKA treatment for ≥3 months. VKA naïve patients should not have received VKA treatment for more than 30 days within the last 12 months. Patients who are not described by either of the above criteria are not eligible for the study
Patients previously treated with acetylsalicylic acid (ASA) for stroke prevention are allowed (and will switch to Apixaban)
Patients with screening mini-mental state examination (MMSE) more than 24
Subject Re-enrollment: This study does not permit the re-enrollment of a subject that has discontinued the study as a pre-treatment failure
Age and Reproductive Status:
Exclusion criteria
Target Disease Exceptions:
Medical History and Concurrent Diseases:
Conditions other than atrial fibrillation that require chronic anticoagulation (e.g., prosthetic mechanical heart valve, venous thromboembolism; also see Section 3.4, Concomitant Treatments)
Patient with serious bleeding in the last 6 months or with a lesion or condition at high risk of bleeding such as:
Primary purpose
Allocation
Interventional model
Masking
1,217 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal